Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 4 | Journal of Orthopaedic Surgery and Research

Fig. 4

From: TNFRSF11B-modified umbilical cord mesenchymal stem cells as a novel strategy for bone-related diseases by suppressing osteoclast activity

Fig. 4

The effect of TNFRSF11B overexpression on osteogenesis of UCMSCs and FOB1.19. (A) Representative images of ALP staining in control or TNFRSF11B-OE transfected UCMSCs following osteogenic induction (Scale bar: 200 μm). (B) Quantification of ALP staining intensity was executed utilizing ImageJ software. (C) The expression levels of RUNX2, OCN, and TNFRSF11B in control and TNFRSF11B-OE UCMSCs were measured through qRT-PCR analysis. Comparisons were made to the control group. *p < 0.05; **p < 0.01. (D) ALP staining of FOB1.19 cells treated with or without UCMSCs-CM (control-CM, TNFRSF11B-OE-CM) for 3 days (Scale bar: 200 μm). (E) ALP staining intensity was quantified using ImageJ software. (F) The expression of osteogenesis-related genes in FOB1.19 cells, with or without control-CM and TNFRSF11B-OE-CM treatment, was examined by qRT-PCR. Blank represents the group without UCMSCs-CM treatment. Comparisons were made to the control group. NS: Not Significant

Back to article page

Journal of Orthopaedic Surgery and Research

ISSN: 1749-799X